Session » Metabolic and Crystal Arthropathies – Basic and Clinical Science Poster II

Date: Tuesday, October 23, 2018

Time: 9:00AM-11:00AM

Meeting: 2018 ACR/ARHP Annual Meeting

9:00AM-11:00AM: Abstract Number: 2228

A Validated Script Concordance Test Demonstrates Interdisciplinary Differences in Clinical Decision-Making When Using Allopurinol to Treat Gout in Chronic Kidney Disease

9:00AM-11:00AM: Abstract Number: 2233

Activation and Deficiency of Circulating Mucosal-Associated Invariant T Cells in Patients with Gouty Arthritis

9:00AM-11:00AM: Abstract Number: 2231

An Ancestral-Specific Interaction of TRIM46 with a Past-History of Smoking May Influence Gout Risk

9:00AM-11:00AM: Abstract Number: 2251

Calcific Tendonitis of the Rotator Cuff: Do We Need Steroid Injection after Ultrasound Guided Percutaneous Lavage? Results of a 12-Months Double-Blind Randomized Controlled Study

9:00AM-11:00AM: Abstract Number: 2229

Can We Predict Inadequate Response to Allopurinol Dose Escalation? Analysis of a Randomized Controlled Trial

9:00AM-11:00AM: Abstract Number: 2253

Cardiovascular Disease, Other Purported Risk Factors, and Allopurinol-Associated Severe Cutaneous Adverse Reactions: A General Population-Based Cohort Study

9:00AM-11:00AM: Abstract Number: 2242

Cardiovascular Outcomes of Treatment with Febuxostat and Allopurinol in Gout Patients with Kidney Disease

9:00AM-11:00AM: Abstract Number: 2217

Clinical Characteristics of Early Onset Gout in Outpatient Setting

9:00AM-11:00AM: Abstract Number: 2244

Comparison of an Interactive Voice Response (IVR) to Smart Phone App to Determine Patient Preference for Reporting Gout Flares

9:00AM-11:00AM: Abstract Number: 2222

Construct Validity of Provisional Remission Criteria for Gout: A Dual Energy CT Study

9:00AM-11:00AM: Abstract Number: 2236

Contemporary Comorbidity Burden of Gout and Hyperuricemia in the US during the Past Decade (National Health And Nutrition Examination Survey [NHANES] 2007-2016)

9:00AM-11:00AM: Abstract Number: 2225

Exploring the Relationship between Gout and Diffuse Idiopathic Skeletal Hyperostosis (DISH): An Epidemiologic and Genetic Study

9:00AM-11:00AM: Abstract Number: 2248

Genetic Variants Identify Interleukin 37 As an Important Anti-Inflammatory Cytokine in Gout in Humans

9:00AM-11:00AM: Abstract Number: 2226

Gout and the Risk of Incident Dementia in the Elderly: A Medicare Claims Study

9:00AM-11:00AM: Abstract Number: 2220

Gout, Flares and Allopurinol Use: A Population Based Study

9:00AM-11:00AM: Abstract Number: 2240

Hip Involvement in Patients with Gout: Results of an Ultrasound Study

9:00AM-11:00AM: Abstract Number: 2255

Increased Cost Burden in an Early Diagnosed Cohort of Uncontrolled Versus Controlled Gout: Analysis of a Large US Payer Database

9:00AM-11:00AM: Abstract Number: 2246

Insulin: Genetic and Physiological Influences on Human Uric Acid Homeostasis

9:00AM-11:00AM: Abstract Number: 2224

Interactions between Serum Urate-Associated Genetic Variants and Sex on Gout Risk in a European Population

9:00AM-11:00AM: Abstract Number: 2234

Liver Safety of Febuxostat Compared with Allopurinol in Gout Patients with Fatty Liver Disease

9:00AM-11:00AM: Abstract Number: 2245

Lubricin/Proteoglycan 4 (PRG4) Inhibits NLRP3 Inflammasome Assembly in Monosodium Urate (MSU)-Crystal Induced Arthritis.

9:00AM-11:00AM: Abstract Number: 2250

Mitigation of Inflammation Induced By Monosodium Urate Crystals in Mice By Treatment with Svp-Rapamycin

9:00AM-11:00AM: Abstract Number: 2235

Monosodium Urate Deposition Distribution in the Knees, Hands, and Feet of Treated Gout Patients: A Dual-Energy CT Study

9:00AM-11:00AM: Abstract Number: 2238

Non-Coding Urate-Associated Variants Function in a Conserved Lincrna Regulatory Domain That Alters MAF transcription

9:00AM-11:00AM: Abstract Number: 2249

Not Just a Swollen Big Toe: Increasing All-Cause Hospitalizations in Patients with Gout in the United States: 1993–2014

9:00AM-11:00AM: Abstract Number: 2247

Predictors of End-Stage Renal Disease (ESRD) in Gout Patients and General Population (GP) Controls – a Role for Interstitial Nephritis, Urate Nephropathy?

9:00AM-11:00AM: Abstract Number: 2232

Prevalence of Gout in the Surviving U.S. Solid Organ Transplant Population

9:00AM-11:00AM: Abstract Number: 2237

Prevalence of Urate-Lowering Therapy Use and Target Urate Level Achievement Among Gout Patients in the United States (National Health And Nutrition Examination Survey [NHANES] 2007-2014)

9:00AM-11:00AM: Abstract Number: 2223

Proton Pump Inhibitors and Risk of Calcium Pyrophosphate Deposition (CPPD) in a Population-Based Study

9:00AM-11:00AM: Abstract Number: 2219

Safety, Pharmacokinetics and Pharmacodynamics of NC-2500, a Novel Xanthine Oxidoreductase Inhibitor, in Healthy Volunteers

9:00AM-11:00AM: Abstract Number: 2252

Serum Urate Ant Its Clearance in Patients with Chronic Kidney Disease Under Peritoneal Dialysis

9:00AM-11:00AM: Abstract Number: 2230

Serum Urate Levels in People with Gout on Dialysis – Are We Achieving Treatment Targets?

9:00AM-11:00AM: Abstract Number: 2243

Sex Difference of the Association between Serum Urate and Blood Pressure in Young Adults

9:00AM-11:00AM: Abstract Number: 2221

Systematic Genetic Analysis of Early-Onset Gout: ABCG2 141K Is the Strongest Predictor

9:00AM-11:00AM: Abstract Number: 2239

Tenocytes Extracted from Rotator Cuff Tendons Are Able to Induce Mineral Deposition in Vitro and Express Genes Related to a Chondrocyte Differentiation

9:00AM-11:00AM: Abstract Number: 2254

Update of SEL-212 Phase 2 Clinical Data in Symptomatic Gout Patients: Svp-Rapamycin Combined with Pegadricase Mitigates Immunogenicity and Enables Sustained Reduction of Serum Uric Acid Levels, Low Rate of Gout Flares and Monthly Dosing

9:00AM-11:00AM: Abstract Number: 2218

Use of Anakinra in Hospitalized Patients with Acute Crystalline Arthritis

9:00AM-11:00AM: Abstract Number: 2241

What Can Variation in Clinical Practice Teach Us about Treatment Strategies for Patients with Gout?

9:00AM-11:00AM: Abstract Number: 2227

What Should be the Goals of Gout Therapy? a Patient Perspective

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].